Treating Multiple Myeloma Patients with Oral Therapies
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important. Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide and...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma: Presentation, Diagnosis and Treatment
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): L. Max Almond, Maria Charalampakis, Samuel Ford, David Gourevitch, Anant Desai Myeloid sarcoma is an extramedullary tumour of immature granulytic cells. It is a rare condition, most often associated with acute myeloid leukaemia although in some rare cases it may present in non-leukaemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with Chronic Lymphocytic Leukemia – indirect comparison
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Iga Andrasiak, Justyna Rybka, Wanda Knopinska-Posluszny, Tomasz Wrobel (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Waldenstr öm Macroglobulinemia: Review of Pathogenesis and Management
Publication date: Available online 7 March 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Seongseok Yun, Ariel Johnson, Onyemaechi Okolo, Stacy J. Arnold, Ali McBride, Ling Zhang, Rachid C. Baz, Faiz Anwer Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M (IgM). Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of n...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial
Conclusions These data demonstrate that in contrast to historically poor results with standard influenza vaccination, this novel high-dose booster vaccination strategy leads to high rates of seroprotection. Randomized controlled studies are needed to compare this to standard vaccination strategy. Teaser The goal of the present study was to evaluate a novel prospective influenza vaccination strategy in patients with plasma cell disorders. Fifty-one patients were treated with a two dose series of high-dose inactivated trivalent influenza vaccine. This vaccination strategy was well tolerated led to very high rates of seroprot...
Source: Clinical Lymphoma Myeloma and Leukemia - March 7, 2017 Category: Cancer & Oncology Source Type: research

Thoracic Complications in Chronic Lymphocytic Leukemia (Thoracic Diseases in CLL)
Publication date: Available online 17 February 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Background Chronic Lymphocytic Leukemia (CLL) is the most common lymphoproliferative disorder worldwide. While thoracic complications are frequent in CLL, only limited data exist regarding the etiologies of these complications. Methods A retrospective chart review was performed on all patients admitted to a tertiary care, CLL-referral center, with CLL and a respiratory complaint from 2001 through 2013 to categorize pulmonary complaints and diagnoses. Fi...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Clinical features and prognosis analysis of Hodgkin ’s lymphoma: A multicenter retrospective study over a decade of patients in China
Conclusions General clinical features were comparable to western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 abnormalities in B-Cell Acute Lymphoid Leukemia
Publication date: Available online 17 February 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Priya Khoral, Eshetu G. Atenafu, Kenneth J. Craddock, Aaron Schimmer, Hong Chang The impact of monosomal karyotype (MK), complex karyotype (CK) and chromosome 17 abnormalities (abnl 17) on prognosis in B-cell acute lymphoid leukemia (B-ALL) has not yet been established. We conducted a retrospective analysis of prognostic factors on 237 adult patients with B-ALL treated at our institution. Older age (>60), higher white blood cell count (>30), and abnl 17 were associated with shorter overall survival on...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2017 Category: Cancer & Oncology Source Type: research

Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients
Conclusions Although ZA did not improve OS in patients with MM; continue to be useful to reduce skeletal events, thus improving better quality of life to the setting of patients. Teaser To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer durat...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Whole Body MR imaging: A Useful Imaging Modality in the Management of Children with Acute Myeloid Leukemia
Conclusion Chloromas tended to show multiplicity and be presented without symptoms. The most common site of involvement was musculoskeletal system. Whole body MR imaging provided additional information that affected clinical management in children with AML. Teaser Children with acute myeloid leukemia suffer from various complications such as chloromas and disseminated infection or inflammation during their illness. As these complications tend to involve everywhere in the body, whole body MR imaging may be a useful tool in children with acute myeloid leukemia. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Systemic Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
Conclusion Incidence and survival of ALK positive ALCL varies significantly with patients’ demographic characteristics as identified in our study. Treatment strategies need to be tailored accordingly to address these variations and ensure uniform access to care. Teaser We used the SEER database to study the incidence and survival of ALK positive ALCL. We found that the disease incidence varied significantly by age, gender and race, while survival was influenced by age, race, stage, period of diagnosis and radiotherapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

The Dana Farber Consortium Protocol (DFCP) for the treatment of adolescents and young adults with acute lymphoblastic leukemia: a single institution experience in Saudi Arabia
Conclusion Although it might be feasible to use pediatric-inspired protocols in this age group, toxicity cannot be overlooked, and the application of these protocols might require modification of drug doses or schedules relative to those used for younger children. Moreover, additional surveillance and supportive measures should be implemented to maximize benefits while minimizing toxicity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies
We present a single-center, large cohort, retrospective study of the efficacy of involved field radiation therapy (IFRT) in ocular adnexal lymphoproliferative disorders (OALDs). Failure free survival (FFS), complete remission (CR), and local, regional and distant failure were determined for 112 patients with marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) OALDs (n=71) and non-MALT OALDs (n=41) cohorts. Fifty-six patients with MALT OALD and 26 patients with non-MALT OALD received IFRT only (without any planned concurrent or sequential systemic chemo- or chemo-immunotherapies). Among these OALD cohorts tre...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
Conclusion Our results lead us to conclude that generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. However, first-line generic imatinib showed suboptimal efficacy compared to branded imatinib. Teaser We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on...
Source: Clinical Lymphoma Myeloma and Leukemia - February 15, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States
Conclusion The diagnostic workup for PTCL in the United States varies widely and often lacks important phenotypic information to fully characterize the lymphoma. Gaps in testing of selected markers should be filled, given the impending revision to the World Health Organization classification. The accuracy of diagnosis will become increasingly important as we enter the era of targeted treatment for PTCL. Micro-Abstract With increased understanding of the unique entities of peripheral T-cell lymphoma (PTCL), subtype-specific approaches are emerging, and more precise diagnoses are becoming increasingly important. Using d...
Source: Clinical Lymphoma Myeloma and Leukemia - February 13, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
Publication date: Available online 11 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sid Selim, Jerome Rey, Aude Charbonnier, Evelyne D'Incan, Bilal Mohty, Didier Blaise, Norbert Vey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 9, 2017 Category: Cancer & Oncology Source Type: research

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
Conclusion To the best of our knowledge, the present study is the first description of PRES associated with DA-EPOCH. The key risk factors for the development of PRES identified in our study included hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, a high tumor burden, and the presence of pre-existing CNS insults during chemotherapy, such as CNS infection. Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment. Micro-Abstract The purpose of our study was to identify risk factors for the development of posterior ...
Source: Clinical Lymphoma Myeloma and Leukemia - February 4, 2017 Category: Cancer & Oncology Source Type: research

Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
Conclusion WT1 expression status represents a good molecular marker of prognosis, response to treatment, and MRD monitoring. Above all, the usage of the WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients could lead to more adapted, personalized treatment protocols. Micro-Abstract The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpress...
Source: Clinical Lymphoma Myeloma and Leukemia - February 2, 2017 Category: Cancer & Oncology Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age
Conclusion Age should not be a limiting factor in considering the modality of AHCT. However, younger patients might also benefit from additional novel treatment approaches in the setting of clinical trials, given their similar outcomes with the older patients in our study. Micro-Abstract Autologous hematopoietic cell transplantation has been shown to prolong survival in patients with multiple myeloma; however, adequate data are lacking for patients aged > 70 years and < 50 years. We retrospectively analyzed and compared the outcomes of patients between the 2 age groups (> 70 vs. ≤ 50 years...
Source: Clinical Lymphoma Myeloma and Leukemia - January 30, 2017 Category: Cancer & Oncology Source Type: research

Myeloma in the Real World: What Is Really Happening?
Publication date: Available online 26 December 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequen...
Source: Clinical Lymphoma Myeloma and Leukemia - January 29, 2017 Category: Cancer & Oncology Source Type: research

The Society of Hematologic Oncology (SOHO): Continuing to Move Forward in the Battle against Hematologic Malignancies
Publication date: Available online 18 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 18, 2017 Category: Cancer & Oncology Source Type: research

Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage IIE extranodal nasal type NK/T cell lymphoma : a study of two centers
Conclusion The results showed that the LOP regimen is safe and much more efficient than CHOP regimen for stage IIE ENKTL patients. It indicates that LOP regimen is a satisfying alternative protocol among the other L-asparaginase-based regimens reported so far, such as SMILE, GELOX, CHOP-L and Sandwich. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicener prospective observational study
Conclusion The QOL among patients on nilotinib administered as a second-line therapy was very good and adherence to the treatment was high. The efficacy and safety of the drug were confirmed in the real-life setting. Teaser To evaluate quality-of-life (QOL) and adherence to Nilotinib used as a second line therapy in 177 chronic myeloid leukemia patients in chronic phase a multicenter, prospective observational study was conducted. The QOL was very good and adherence to the treatment was high. Study results could be taken into consideration in the process of TKI treatment choice (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy
Conclusion To our knowledge, this is the first description of PRES associated with DA-EPOCH. Key risk factors for development of PRES identified in our study include hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, high tumor burden and presence of preexisting CNS insults during chemotherapy treatment such as CNS infection. Patients with these risk factors appear to be at higher risk of developing PRES and should be monitored closely during treatment. Teaser The purpose of our study was to identify risk factors for development of posterior reversible encephalopathy syndrome (PRES) follo...
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

More about the risk of Ibrutinib-associated bleeding
Publication date: Available online 10 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ambra Paolini, Valeria Coluccio, Mario Luppi, Marco Marietta (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Peripheral T-Cell Lymphoma Diagnostic Work-Up in the United States
Conclusion The diagnostic work-up for PTCL in the US is widely variable, often lacking important phenotypic information to fully characterize the lymphoma. Gaps in testing of selected markers will need to be filled given the impending revision to the WHO classification. Accuracy of diagnosis will become increasingly important as we enter the era of targeted treatment for PTCL. Teaser With increased understanding of unique entities of peripheral T-cell lymphomas (PTCL), subtype specific approaches are emerging and more precise diagnoses is becoming increasingly important. Using data from a large prospective cohort study, we...
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Evidence for Selective Benefit of Sequential Treatment with Hypomethylating agents in Patients with Myelodysplastic Syndrome (MDS)
Conclusions Enrollment in clinical trial should be the strongly encouraged in HMA failure. Sequential use of HMA could be considered as an alternative approach in the treatment of MDS after first line HMA failure if clinical trials are not available. The outcome of patients with progressive disease after treatment with HMA remains poor and continues to be an unmet need. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Treatment of post transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy
Publication date: Available online 11 January 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Selim Sid, Rey Jerome, Charbonnier Aude, D’Incan Evelyne, Mohty Bilal, Blaise Didier, Norbert Vey (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Usage of Wilms ’ Tumor 1 (WT1) Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Normal Karyotype (AML-NK) Patients
Conclusion WT1 expression status represents a good molecular marker of prognosis, response to treatment evaluation and MRD monitoring. Above all, the usage of WT1 expression level as an additional marker for more precise risk stratification of AML-NK patients, can lead to more adapted, personalized treatment protocols. Teaser The aim of this study was to test the possibility for the usage of WT1 expression level as an additional biomarker for prognosis and minimal-residual-disease (MRD) monitoring in AML-NK patients. We found that overexpression of WT1 had negative impact on treatment outcome. It was a suitable marker for ...
Source: Clinical Lymphoma Myeloma and Leukemia - January 10, 2017 Category: Cancer & Oncology Source Type: research

Myeloma in the Real World: What ’s really happening?
Publication date: Available online 26 December 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Multiple myeloma (MM) is the second most common haematological malignancy and predominantly a disease of the elderly. In the last two decades a range of new therapeutic options have become available leading to improvements in patient outcomes including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach towards more active management including use of sequential ...
Source: Clinical Lymphoma Myeloma and Leukemia - December 26, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Implications of Monosomies in Patients with Multiple Myeloma
Conclusion In addition to known cytogenetic abnormalities, such as monosomy 13, hypodiploidy and TP53 (17p) deletion, monosomy 16, and loss of the Y chromosome have adverse prognostic implications in patients with MM. Teaser This study evaluated the prevalence and prognostic implications of monosomies in 170 Korean patients with multiple myeloma (MM). Monosomies in chromosomes 16, chromosomes 13, TP53 (17p) deletion, and hypodiploidy had adverse prognostic implications in patients with MM. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 25, 2016 Category: Cancer & Oncology Source Type: research

Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients
Conclusion Results support existing registry data demonstrating that survival for HL has improved over the 4 decades analyzed. This data set is robust and validated, and it adds valuable understanding to the reasons behind the survival curves, which are a balance between efficacious therapies and decreased death related to cardiac conditions and second malignancies. Micro-Abstract Survival for Hodgkin lymphoma has improved over the last 4 decades thanks to reducing the risks of death from primary disease and, expectantly, treatment-related toxicity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 24, 2016 Category: Cancer & Oncology Source Type: research

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study
Conclusion The present study provides the first known comparison of cardiac event risk in patients with MM versus age- and gender-matched patients without MM. The cardiac event risk was greater in MM patients with ≥ 3 previous drugs for any cardiac event, dysrhythmias, congestive heart failure, cardiomyopathy, and conduction disorders compared with patients without MM. Micro-Abstract The present study provides a unique look at real world cardiac event rates for a large group of multiple myeloma (MM) patients treated with selected anti-MM treatments. The cardiac event risk for any cardiac event, including hypertensi...
Source: Clinical Lymphoma Myeloma and Leukemia - December 23, 2016 Category: Cancer & Oncology Source Type: research

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma
Conclusion Our data, although from a small series, suggest that the blood ACD4C might be a predictor of PFS for patients with DLBCL, independent of age and the IPI. Micro-Abstract Immune cell subsets in the blood of patients with diffuse large B-cell lymphoma before therapy were characterized by flow cytometry, and the levels of various T-cell types and natural killer cells were correlated with the eventual outcomes. High absolute levels of CD4 cells in the blood correlated with better progression-free survival and, to a lesser extent, overall survival, independent of patient age and International Prognostic Index score. (...
Source: Clinical Lymphoma Myeloma and Leukemia - December 23, 2016 Category: Cancer & Oncology Source Type: research

Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era
Conclusion Patients with relapsed or refractory DLBCL experiencing relapse > 1 year after ASCT had good outcomes. Despite the relative rarity in incidence, a significant risk of relapse of DLBCL after ASCT remains, suggesting the need for continued monitoring because of the possibility of later progression. Micro-Abstract The standard of care for diffuse large B-cell lymphoma (DLBCL) relapsing after front-line therapy is high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients with relapsed or refractory DLBCL experiencing relapse > 1 year after ASCT had good outcomes. Despite the rela...
Source: Clinical Lymphoma Myeloma and Leukemia - December 18, 2016 Category: Cancer & Oncology Source Type: research

Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis
Conclusion Overall, despite the older age and a greater number of patients with high-risk category (including Philadelphia chromosome-positive) in the hyper-CVAD group, this did not translate into a difference in survival outcome between the 2 groups. The hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. Micro-Abstract Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We show that the hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen appears to be feasible f...
Source: Clinical Lymphoma Myeloma and Leukemia - December 14, 2016 Category: Cancer & Oncology Source Type: research

Low Level of Blood CD4+ T-Cells Is An Independent Predictor of Inferior Progression Free Survival in Diffuse Large B-Cell Lymphoma
Conclusion Our data, though a small series, suggest that blood ACD4C may be a predictor of PFS in DLBCL, independent of age and IPI. Teaser Immune cell subsets in blood of patients with diffuse large B cell lymphoma prior to therapy were characterized by flow cytometry and levels of various T-cell types and NK cells correlated with eventual outcomes. High absolute levels of CD4 cells in blood correlated with better progression free survival, and to a lesser extent overall survival, independent of age and IPI. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 29, 2016 Category: Cancer & Oncology Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Impact of Age
Publication date: Available online 25 November 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D’Souza, Parameswaran Hari In both the novel and pre-novel agent era, high dose therapy followed by autologous hematopoietic cell transplant (AHCT) has been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients 65 years and younger. Given the median age at diagnosis is 66 years, it is important to know the outcomes of AHCT in older pa...
Source: Clinical Lymphoma Myeloma and Leukemia - November 24, 2016 Category: Cancer & Oncology Source Type: research

Acute Leukemia of Ambiguous Lineage in Elderly Patients – Analysis of Survival using Surveillance Epidemiology and End Results-Medicare Database
Conclusion Our study suggests that the OS of elderly patients with ALAL remains poor. Although treatment improved the OS, only 21.5% of patients received therapy. Optimal choice of therapy needs to be determined by prospective studies. Teaser We used the SEER-Medicare database to study the overall survival and treatment pattern of elderly patients with acute leukemia of ambiguous lineage in United States. Overall survival of this leukemia remains poor, but is improved significantly with chemotherapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 22, 2016 Category: Cancer & Oncology Source Type: research

Practical Considerations in Managing Relapsed Multiple Myeloma
Publication date: Available online 23 November 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Amit Agarwal, Eric Chow, Manisha Bhutani, Peter M. Voorhees, Reed Friend, Saad. Z. Usmani Considerable advances have been made in the treatment of relapsed and relapsed/refractory multiple myeloma (RRMM), with numerous novel agents and combination strategies receiving regulatory approvals worldwide over the last several years. An increasing body of phase III data clearly demonstrates increased overall response rates, improved depths of response and more durable responses when a third novel agent is incorporated int...
Source: Clinical Lymphoma Myeloma and Leukemia - November 22, 2016 Category: Cancer & Oncology Source Type: research

Late Relapses following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era
Conclusions Patients with relapsed or refractory DLBCL experiencing relapse >1 year post-ASCT had good outcomes. Despite the relative rarity in incidence, there remains a significant risk of relapse of DLBCL post-ASCT, suggesting the need for continued monitoring for the possibility of later progression. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 22, 2016 Category: Cancer & Oncology Source Type: research

The incidence and risk of cardiac events in patients with previously treated multiple myeloma vs. matched patients without multiple myeloma: an observational, retrospective, cohort study
Conclusions This study provides the first known comparison of cardiac event risk in MM patients vs. age- and gender-matched patients without MM. Cardiac event risk was greater in MM patients with ≥3 prior drugs for any cardiac event, dysrhythmias, CHF, cardiomyopathy, and conduction disorders compared to patients with non-MM. Teaser This study provides a unique look at real world cardiac event rates for a large group of MM patients treated with selected anti-myeloma treatments. Cardiac event risk for any cardiac event including hypertensive/arterial events, cardiac dysrhythmias, CHF, IHD, cardiomyopathy, and conduction ...
Source: Clinical Lymphoma Myeloma and Leukemia - November 21, 2016 Category: Cancer & Oncology Source Type: research

Change in IGHV Mutational Status of CLL Suggests Origin from Multiple Clones
Publication date: Available online 21 November 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Afaf Osman, Christopher D. Gocke, Douglas E. Gladstone (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 20, 2016 Category: Cancer & Oncology Source Type: research

The Improving Survival of Patients with Hodgkin Lymphoma Over Four Decades – Experience of the British National Lymphoma Investigation (BNLI) with 6834 Patients
Conclusion These results support existing registry data demonstrating that survival for Hodgkin lymphoma has improved over the four decades described. This data set is robust and validated, and adds valuable understanding to the reasons behind the survival curves, which are a balance between efficacious therapies and decreased death related to cardiac conditions and second malignancies. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 20, 2016 Category: Cancer & Oncology Source Type: research

Hyper-CVAD compared to BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective single center analysis
Conclusion Overall, despite the older age and a higher number of patients with high risk category (including Ph+) in the hyper-CVAD group, this did not translate into a difference in survival outcome between the 2 groups. The hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. Teaser Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We demonstrate that the hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. Addition of TKI for Ph+ cases and rituximab for ...
Source: Clinical Lymphoma Myeloma and Leukemia - November 20, 2016 Category: Cancer & Oncology Source Type: research

A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients with Clinical or Laboratory Tumor Lysis Syndrome
Conclusions In this analysis of TLS patients receiving care in real-world settings, rasburicase vs allopurinol was significantly more effective in treating hyperuricemia and was associated with significantly shorter ICU and overall hospital stays and lower total inpatient costs. Teaser Management of tumor lysis syndrome (TLS), a potentially fatal oncologic complication following initiation of chemotherapy or other cytotoxic treatment or occurring spontaneously before treatment, has significant economic impact. This retrospective study of hospital administrative data from pediatric and adult patients with laboratory or clin...
Source: Clinical Lymphoma Myeloma and Leukemia - November 20, 2016 Category: Cancer & Oncology Source Type: research

Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia
Conclusion Our analysis shows AYAs with AML have worse EMR and OS compared with pAMLs. AYAs with APL and pAPLs have similar outcomes. To our knowledge, this is the first study reporting outcomes of AYAs with APL and pAPLs using a large population-based registry and their comparison with same age patients with AML. Micro-Abstract Studies on the outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited. We compared outcomes of AYAs (age, 19-30 years) and pediatric (age, 0-18 years) patients with AML and APL using the Surveillance, Epidemiology, and End...
Source: Clinical Lymphoma Myeloma and Leukemia - November 8, 2016 Category: Cancer & Oncology Source Type: research

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US  Community Oncology Practices
Conclusions As expected, OS in patients receiving low-intensity therapy or BSC with HU is poor for elderly patients with AML. Remarkably, intensive induction strategies are rarely used for older patients in community oncology practice. Micro-Abstract This retrospective observational study of data from the US community oncology setting evaluates real-world treatment patterns and outcomes for newly diagnosed, elderly patients with acute myeloid leukemia. The analysis focuses on those patients who did not receive standard induction therapy (“3 + 7”–type regimens). (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - November 4, 2016 Category: Cancer & Oncology Source Type: research

Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms
Publication date: November 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Issue 11 Author(s): John M. Bennett In comparison with the 2008 World Health Organization “Blue Book” on hematopoietic neoplasms, a small number of changes have been made in the classification. In the lower-risk patients, Refractory Cytopenias with Multilineage Dysplasia and Ring Sideroblasts (RCMD-RS) has been separated from RCMD to recognize the importance of the SF3B1 mutation. Often there has been confusion as to the degree of morphologic dysplasia and/or cytopenias to define some of the lower-risk subtypes. In additi...
Source: Clinical Lymphoma Myeloma and Leukemia - November 4, 2016 Category: Cancer & Oncology Source Type: research

Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders
Conclusion Age at diagnosis, elevated creatinine, white race, and OKT3 were associated with inferior survival in patients with PTLD-MM. Survival of PTLD-MM is inferior to SEER-MM, although significant improvements in survival have been documented. Micro-Abstract We identified in a large database 212 patients with multiple myeloma (MM) that developed after solid organ transplantation, which is a rare form of posttransplantation lymphoproliferative disorder (PTLD-MM), and we examined overall survival and prognostic factors. PTLD-MM has a worse prognosis than MM, but improvement in survival over time outpaced that of MM over ...
Source: Clinical Lymphoma Myeloma and Leukemia - October 20, 2016 Category: Cancer & Oncology Source Type: research